Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0MH8O
|
|||
| Former ID |
DIB009302
|
|||
| Drug Name |
Angiotensin-(1-7)
|
|||
| Synonyms |
Ang (1-7); Angiotensin (1-7); Angiotensin-(1-7) (cancer); Angiotensin-(1-7) (cancer), Wake Forest University
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Sarcoma [ICD-11: 2A60-2C35; ICD-10: C81-C86; ICD-9: 202.8] | Phase 3 | [1], [2] | |
| Chemotherapy-induced nausea [ICD-11: MD90; ICD-10: R11] | Phase 2 | [3] | ||
| Duchenne dystrophy [ICD-11: 8C70; ICD-10: G71.0] | Phase 2 | [4] | ||
| Lymphoma [ICD-11: 2A80-2A86] | Phase 2 | [3] | ||
| Muscular dystrophy [ICD-11: 8C70; ICD-10: G71.0] | Phase 1 | [4] | ||
| Company |
Tarix pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C41H62N12O11
|
|||
| Canonical SMILES |
CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N
|
|||
| InChI |
1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1
|
|||
| InChIKey |
PVHLMTREZMEJCG-GDTLVBQBSA-N
|
|||
| CAS Number |
CAS 39386-80-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14889691, 14938661, 29303996, 47205170, 50070389, 50070541, 50071317, 50112515, 74375902, 80118902, 87351979, 104419365, 126686943, 134223321, 135079217, 135232468, 135651614, 136351656, 137156831, 163423858, 184605749, 223672217, 240852277, 241091408, 241182531, 241375500, 249617335, 252392657, 252477658
|
|||
| ChEBI ID |
CHEBI:55438
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proto-oncogene Mas (MAS) | Target Info | Agonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Renin-angiotensin system | ||||
| WikiPathways | ACE Inhibitor Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 582). | |||
| REF 2 | New therapeutic pathways in the RAS. J Renin Angiotensin Aldosterone Syst. 2012 Dec;13(4):505-8. | |||
| REF 3 | ClinicalTrials.gov (NCT01121120) Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients. U.S. National Institutes of Health. | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.